Abstract:Fluoroquinolone resistance in Mycoplasma hominis and Ureaplasma spp. is on the rise globally, which has compromised the efficacy of the currently available antimicrobial agents. This study evaluated the antimicrobial activity of two new fluoroquinolones, delafloxacin and finafloxacin, for the first time, against M. hominis and Ureaplasma spp. clinical isolates. The in vitro activity of two new fluoroquinolones, delafloxacin and finafloxacin, were evaluated against M. hominis and Ureaplasma spp. The MICs of delafloxacin, finafloxacin, and two classical fluoroquinolones (moxifloxacin and levofloxacin) were tested against 29 M. hominis and 67 Ureaplasma spp. isolates using the broth microdilution method. The molecular mechanisms underlying fluoroquinolone resistance were also investigated. Delafloxacin exhibited low MICs against M. hominis and Ureaplasma spp., including the levofloxacin-resistant isolates. For M. hominis, delafloxacin showed low MIC90 value of 1 mu g/mL (MIC range, <0.031 -1 mu g/mL) compared to 8 mu g/mL for finafloxacin, 16 mu g/mL for moxifloxacin, and 32 mu g/mL for levofloxacin. For U. parvum and U. urealyticum, delafloxacin had low MIC90 values (U. parvum, 2 mu g/mL; U. urealyticum, 4 mu g/mL) compared to 16 -32 mu g/mL for finafloxacin, 16 mu g/mL for moxifloxacin, and 32 - >32 mu g/mL for levofloxacin. The two mutations GyrA S153L and ParC S91I were commonly identified in fluoroquinolone-resistant M. hominis, and ParC S83L was the most frequent mutation identified in fluoroquinolone-resistant Ureaplasma spp. Delafloxacin displayed lower MICs against fluoroquinolone-resistant isolates of both M. hominis and Ureaplasma spp. that have mutations in the quinolone resistance determining regions (QRDRs) than the two classical fluoroquinolones. Delafloxacin is a promising fluoroquinolone with low MICs against fluoroquinolone-resistant M. hominis and Ureaplasma spp. Our study confirms the potential clinical use of delafloxacin in treating antimicrobial-resistant M. hominis and Ureaplasma spp. infections. IMPORTANCE Fluoroquinolone resistance in Mycoplasma hominis and Ureaplasma spp. is on the rise globally, which has compromised the efficacy of the currently available antimicrobial agents. This study evaluated the antimicrobial activity of two new fluoroquinolones, delafloxacin and finafloxacin, for the first time, against M. hominis and Ureaplasma spp. clinical isolates. Delafloxacin and finafloxacin displayed different antimicrobial susceptibility profiles against M. hominis and Ureaplasma spp. in vitro. Delafloxacin was found to be more effective against M. hominis and Ureaplasma spp. than three classical fluoroquinolones (finafloxacin, moxifloxacin, and levofloxacin). Finafloxacin displayed activity similar to moxifloxacin but superior to levofloxacin against M. hominis and Ureaplasma spp. Our findings demonstrate that delafloxacin is a promising fluoroquinolone with outstanding activity against fluoroquinolone-resistant M. hominis and Ureaplasma spp.

In vitro antibacterial activity of DX-619, a novel Des-F (6)-quinolone against clinical isolates in China.

In vitro activity of flomoxef and comparators against Escherichia coli, Klebsiella pneumoniae and Proteus mirabilis producing extended-spectrum β-lactamases in China

<i>In Vitro</i> Activity of Delafloxacin and Finafloxacin against Mycoplasma hominis and <i>Ureaplasma</i> Species

In vitro antibacterial activity of Du6859a

In vitro and in vivo antibacterial activities of DK-507k, a novel fluoroquinolone

In Vitro Activity of MRX-8 and Comparators Against Clinical Isolated Gram-Negative Bacilli in China

Comparative Activities of Sitafloxacin Against Recent Clinical Isolates in Hospitals Across China

2373. Evaluation of Delafloxacin Activity and Treatment Outcome for Phase 3 Acute Bacterial Skin and Skin Structure Infection Clinical Trial Anaerobic Isolates

Evaluation of the in vitro activity of new polymyxin B analogue SPR206 against clinical MDR, colistin-resistant and tigecycline-resistant Gram-negative bacilli.

In vitro activity of cefminox and comparators against Escherichia coli, Klebsiella pneumoniae and Bacteroides species

In vitro activity of cefditoren and other comparators against Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis causing community-acquired respiratory tract infections in China.

High antipersister activity of a promising new quinolone drug candidate in eradicating uropathogenic Escherichia coli persisters and persistent infection in mice

In vitro antibacterial activity of azlocillin and other eight antimicrobials against 898 bacteria isolated in Shanghai and Beijing

Novel Quinoxaline Derivatives: Design, Synthesis, Bioactive Evaluation, SARs, and Preliminary Antibacterial Mechanism

In Vitro Activity of KBP-7072 against 536 Acinetobacter baumannii Complex Isolates Collected in China

The discovery of 1, 3-diamino-7H-pyrrol[3, 2-f]quinazoline compounds as potent antimicrobial antifolates

In Vitro and in Vivo Activities of a Novel Β-Lactamase Inhibitor Combination Imipenem/xnw4107 Against Recent Clinical Gram-negative Bacilli from China.

Study in Vitro of Antimicrobial Activity of Domestic Sparfloxacin

Antibacterial and anti-biofilm activity of radezolid against Staphylococcus aureus clinical isolates from China

Identification of CH2-linked Quinolone-Aminopyrimidine Hybrids As Potent Anti-Mrsa Agents: Low Resistance Potential and Lack of Cross-Resistance with Fluoroquinolone Antibiotics

Design, Synthesis, Antibacterial Evaluation and Docking Study of Novel 2‐hydroxy‐3‐(nitroimidazolyl)‐propyl‐derived Quinolone